Adage Capital Partners GP L.L.C. Makes New Investment in Septerna, Inc. (NASDAQ:SEPN)

Adage Capital Partners GP L.L.C. purchased a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 300,000 shares of the company's stock, valued at approximately $6,870,000. Adage Capital Partners GP L.L.C. owned approximately 0.68% of Septerna as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD bought a new position in Septerna during the fourth quarter worth about $11,877,000. Avoro Capital Advisors LLC acquired a new stake in shares of Septerna during the fourth quarter worth about $25,419,000. Tower Research Capital LLC TRC bought a new position in shares of Septerna during the 4th quarter valued at about $25,000. TRV GP V LLC acquired a new position in shares of Septerna in the 4th quarter valued at approximately $142,337,000. Finally, TRV GP VI LLC bought a new stake in Septerna during the 4th quarter worth approximately $72,191,000.

Insider Activity

In other news, Director Alan Ezekowitz purchased 7,491 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was purchased at an average price of $6.35 per share, for a total transaction of $47,567.85. Following the completion of the purchase, the director now directly owns 24,911 shares in the company, valued at $158,184.85. The trade was a 43.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gil M. Labrucherie acquired 5,000 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was purchased at an average cost of $5.85 per share, with a total value of $29,250.00. Following the transaction, the chief financial officer now owns 30,000 shares in the company, valued at approximately $175,500. This trade represents a 20.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 74,346 shares of company stock worth $439,670 in the last quarter.

Septerna Stock Up 4.8 %

NASDAQ:SEPN traded up $0.34 during trading hours on Friday, reaching $7.48. 202,765 shares of the stock were exchanged, compared to its average volume of 420,448. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The company's 50 day simple moving average is $6.10.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. The business had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.13 million. As a group, analysts anticipate that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on SEPN shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $50.00 price target on shares of Septerna in a report on Tuesday, February 11th. Wells Fargo & Company reduced their target price on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research note on Friday, March 28th.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.